Clinical Trial Update: Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of adalimumab in moderately to severely active psoriatic arthritis has completed. The study was sponsored by …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Arthritis, Psoriatic | Phase 2 | Status: COMPLETED